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We describe a large family in which a combination of chronic mucocutaneous candidiasis (fungal infections of the
skin, nails, and mucous membranes) and thyroid disease segregate as an autosomal dominant trait with reduced
penetrance. The family includes (a) four members with both candidiasis and thyroid disease, (b) five members,
including one pair of phenotype-concordant MZ twins, with candidiasis only, and (c) three members with thyroid
disease only. A whole-genome scan using DNA samples from 20 members of the family identified a candidate
linkage region on chromosome 2p. By sampling additional individuals and genotyping supplementary markers, we
established linkage to a region of ∼15 cM bounded by D2S367 and D2S2240 and including seven adjacent markers
consistent with linkage. With a penetrance estimate of .8, which was based on pedigree and affected status, the
peak two-point LOD score was 3.70 with marker D2S2328, and the peak three-point LOD score was 3.82. This
is the first linkage assignment of a dominant locus for mucocutaneous candidiasis.
Introduction
Chronic mucocutaneous candidiasis (CMC) is a well-
recognized clinical syndrome in which patients exhibit
increased susceptibility of skin, nails, and mucous mem-
branes to infections by Candida albicans and dermat-
ophyte fungi, mainly of the genera Trichophyton and
Microsporum. Most cases of CMC are sporadic. A clas-
sification of CMC syndromes, proposed by Kirkpatrick
(2001), is based on the location of infections and on the
presence of accompanying clinical findings. Although
CMC is often secondary to other medical conditions,
such as HIV infection, steroid use, or iron deficiency,
primary CMC has been reported to have a genetic basis,
either dominant or recessive (MIM 114580 and MIM
212050, respectively) (Wells et al. 1972; Kroll et al.
1973; Sams et al. 1979; Loeys et al. 1999). CMC is often
accompanied by endocrine or inflammatory disorders,
suggesting dysregulation of the immune system. The oc-
currence and age at onset of fungal infections and other
features is variable, even among affected members of a
family. Moreover, genetic analysis has not been facili-
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tated by laboratory evaluations; patients with CMC of-
ten lack immunologic abnormalities that can be readily
diagnosed by routine laboratory tests, although skin
tests and in vitro proliferation and cytokine production
in response to candida antigens tend to be low or absent.
Starting with the first documented report in the lit-
erature (Thorpe and Handley 1929), a high prevalence
of endocrinopathies has been noted in patients with
CMC (Thorpe and Handley 1929; Sutphin et al. 1943;
Whitaker et al. 1956). To date, the only gene associat-
ed with CMC, AIRE (autoimmune regulator), is the
disease gene for the autosomal recessive syndrome au-
toimmune polyendocrinopathy-candidiasis-ectodermal
dystrophy, or APECED (MIM 240300) (Ahonen 1985;
Nagamine et al. 1997; The Finnish-German APECED
Consortium 1997). Although patients with APECED
may exhibit a wide range of endocrinopathies, they typ-
ically develop hypoparathyroidism and/or adrenal fail-
ure. Patients with hyper-IgE syndrome, which can be
inherited in autosomal dominant fashion, have also
been shown to exhibit fungal infections of the oro-
pharynx and nails, suggesting that this form of immune
deficiency is also associated with CMC (Van Scoy et al.
1975; Grimbacher et al. 1999a, 1999b). However, en-
docrinopathies are not a common feature of hyper-IgE
syndrome.
The present article describes a family in which CMC
is associated with thyroid disease. The family includes
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Figure 1 Partial pedigree segregating CMC (symbols with right half blackened) and thyroid disease (symbols with left half blackened),
showing subjects contributing DNA for both phases of analysis (black dots above symbols) or for fine mapping only (white dots above symbols).
Individuals for whom CMC was unknown are denoted by symbols enclosed within square brackets. Generation V (not shown) contained four
children who were too young for phenotype assignment but whose DNA was genotyped. There was anecdotal evidence that one or more spouses
of III-5 were related to individuals in generation II, but we were unable to confirm the relationship(s). Therefore, the father of twins IV-2 and
IV-3, the father of IV-4, and the father of IV-5 were designated as unaffected, ungenotyped men with a low likelihood of carrying the disease
allele.
(a) four members with both candidiasis and thyroid dis-
ease, including one with the uncommon condition Riedel
thyroiditis; (b) five members, including a pair of phe-
notype-concordantMZ twins, with candidiasis only; and
(c) three members with thyroid disease only. Under a
model of autosomal dominant inheritance, there are also
two nonpenetrant obligate carriers in the family, as well
as young children at risk for development of disease, for
whom genetic linkage–based diagnosis would confer po-
tential benefit. We established linkage of CMC and/or
thyroid disease in this family to a 15-cM interval on
chromosome 2p.
Subjects and Methods
Subjects
During the past 3 decades, members of a large non-
consanguineous white family have received, at the Uni-
versity of Alabama Medical Center, medical manage-
ment for candidiasis and thyroid disease. A partial
pedigree is shown in figure 1. Members of the family
are not part of a subpopulation recognized to have in-
creased incidence of immune disorders or thyroid dis-
ease. The original probands—the affected father (III-8)
and grandmother (II-4)—were first reported by Montes
et al. (1971). Subject III-8 has severe CMC and was
reported as “patient 2” in a trial of oral amphotericin
B administration (Montes et al. 1971). His mother (II-
4), deceased after developing two separate squamous cell
carcinomas of the face and polycythemia vera, had had
lifelong, severe CMC and required thyroidectomy at age
30 for euthyroid goiter with no anti-thyroid antibodies.
For the present study, 36members of the extended family
enrolled with informed consent in a study approved by
the Institutional Review Board of the National Institutes
of Health. Histories, focused physical examinations, and
blood samples for DNA analysis were obtained for all
enrollees. Subjects were classified as having CMC either
by direct examination or by report of family members.
The skin and nail involvement with candida are illus-
trated in figure 2. Other than two subjects with obvious
thyroid enlargement as well as elevated thyroid-stimu-
lating hormone (TSH) levels, the diagnosis of thyroid
disease was based on a history of diagnosis by a phy-
sician and/or documented laboratory values.
Additional studies of thyroid and immunologic status
were obtained from members of one branch of the fam-
ily. The four siblings—IV-6, IV-7, IV-8, and IV-9—have
been followed, since early childhood, at Children’s Hos-
pital of Alabama. Three of these children have had severe
candida infections of the skin, nails, and mucous mem-
branes, with variable responses to chronic administra-
tion of oral and topical antifungal antibiotics. Cultures
of their lesions have yielded isolates of C. albicans and,
in one instance, Trichophyton species. After sustaining
a burn injury, subject IV-9 developed respiratory failure
and agranulocytosis. Although he recovered and under-
went successful skin grafts after intravenous antibiotic
and antifungal treatment, his course may have been com-
plicated by candida superinfection. No other instance of
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Figure 2 Candida infection of the skin and nails in subjects IV-7 (left) and III-8 (right)
invasive candidal disease in the family was documented.
Subjects IV-7 and IV-8 had elevated levels of thyroid-
stimulating hormone (TSH)—36 and 10.3 mIU/ml, re-
spectively (normal values 0.36–5.8 mIU/ml). The TSH
value in IV-7 normalized after treatment with levothy-
roxine. This child was negative for thyroid peroxidase
and anti-thyroglobulin antibodies, but an ultrasound of
the thyroid revealed multiple cysts, the largestmeasuring
0.5 cm in diameter. Subject IV-7 has also had numerous
warts on the extremities.
Others in the family were diagnosed with hypothy-
roidism, including subject III-14, a man who, in addition
to fungal infections of the skin, mouth, and nails was
diagnosed with Riedel thyroiditis, a fibrosing, invasive
thyroid disease usually seen in older women (Zimmer-
mann-Belsing and Feldt-Rasmussen 1994). No family
member has been diagnosed with hypoparathyroidism,
adrenal failure, or other endocrinopathy.
Immunologic Tests
Skin-test reactivity was assessed by intradermal injec-
tion of 0.1 ml of standard antigens. Serum immunoglob-
ulin levels, isohemagglutinins, and cell-surface phenotyp-
ing by flow cytometry were performed at the Children’s
Hospital of Alabama. Mononuclear cells were isolated,
by standard methods, over Ficoll-Hypaque gradients and
were cultured either with medium alone, with mitogens
phytohemagglutinin (PHA) (Life Sciences), concanavalin
A (ConA) (Sigma) or pokeweed (PWM) (Life Sciences,
Inc), or with either soluble antigen extract from candi-
da (Greer Laboratories) or preservative-free tetanus tox-
oid (Wyeth-Ayerst) (James 1994). For proliferation stud-
ies, cells were cultured in RPMI 1640medium, eitherwith
10% human AB serum alone or with PHA or ConA, for
3 d; cultures with medium, PWM, tetanus, and candi-
da were held for 6 d. For the last 6 h of culture, 3H-
thymidine was added; cells then were harvested, and in-
corporated 3H was measured (James 1994). After 3 d,
interferon (IFN)-g secretion into culture supernatants in
response to PHA was analyzed with a flow-cytometry
bead–assay kit (BioErgonomics). IFN-g and tumor-necro-
sis factor (TNF)-a production were also measured 6 d
after plating of 106 cells in 24-well flat-bottomed tissue
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Table 1
Chromosome 2p Markers Used in Linkage Analysis.
MARKER
SEX-AVERAGED
DISTANCE FROM
2p TELOMERE
(cM)
PRIMER SEQUENCE
(5′r3′)
Forward Reverse
D2S2207 20.57 CAAGACACCTCTGGTCAGATGCC TGCACCACTGAGTTCCAGCC
D2S1400a 27.6 CAAGACACCTCTGGTCAGATGCC TGCACCACTGAGTTCCAGCC
D2S131 31.2 GTATAGGAGCCACACCCCTG TTTACTGCTGAGACAACCCA
D2S1360a 38.33 TAACCTTGTGAGCCAATTCC CAAAACAGAAACAGAACTAATAAGA
D2S320 38.33 CAGCCCAGCCATTGATATTT AACCAACAACTATGCTAGAGATTCC
D2S405a 47.97 GAACAGGATGGGGAAAACTT CAGAAGCGTGGCAGTTTATT
D2S352 50.65 CTACAGGGCTTCAGCATCC GCAAAGTCGTTCTCAGGTG
D2S367 54.96 AGCTTCTTGTTCACAGGTGT TTCTTTGGTCTAAGGGTCAC
D2S1325 54.96 TATGCATGTATGTGTGTATGTATGC TTGCTGCAGACCTGTATGAA
D2S1788a 55.51 AATGGATGGACAAATGGATG CCCTCCATAATTAGATGAGCC
D2S2328 61 CTTTGGCAAACGAGCG CCGAGCAATTTCACTCTGG
D2S1356a 64.29 TTCTTGGGCTCCAGGATG AGGGCAAAACCGCATCTCTA
D2S414 64.84 TACTGACTTCTCTGCTCAGAACA AGCAAAATTAAACTTGGGATATT
D2S119 65.39 GAGAATCCCTCAATTTCTTTGGA CTTGGGGAACAGAGGTCATT
D2S2174 67.58 GACGGGTTAGACTCCTGC TCTTAGAGATGCCCCCA
D2S2240 69.77 GGTGTTACTAAACATCCACAGAG GCGTTGCCCAAAAGAG
D2S2739a 73.61 CTGGTGTTTAGAATATCTGTCTAGG ATCTGTTATTCACTTTAACTGAGGC
D2S337 80.69 TGCTCCTGGCTTATTTCA GTCTGCATTCCCACGA
D2S441a ∼88 AAAAGGCTGTAACAAGGGCT ATTGGAGCTAAGTGGCTGTG
NOTE.—Not included in this table are D2S2221 (at 44.09 cM), which was dropped because of difficulty with PCR
and location outside the ultimate region of interest, and D2S2298 (at 65.94 cM), which was dropped because of
“stuttering,” producing difficulty in allele assignment.
a Used for initial genome scan.
plates in 1 ml RPMI 1640 with 10% fetal bovine serum
and antibiotics with or without either tetanus toxoid (10
mg/ml) or candida antigen (320 mg/ml). After incubation,
the supernatants were removed, filtered, and analyzed for
concentrations of cytokines, by commercial enzyme-
linked immunosorbent–assay kits (Endogen and R&D
Systems, for INF-g and TNF-a, respectively).
Marker Selection and Genotyping
Both the genotyping and DNA-sample ascertainment
were done in two stages. In the first stage, 20 family
members were genotyped at 392 autosomal markers and
at X and Y markers (Center for Inherited Disease Re-
search; K. Doheny, personal communication). Custom-
ized fluorescent primers and PCR conditions were used,
and data were collected by an ABI 377 sequencer using
GENOTYPER software (PE Applied Biosystems) (K.
Doheny, personal communication). In the second stage,
performed in the laboratories of B.G. and J.M.P., 16
additional family members were included. After enroll-
ment of the second set of participants, one individual
was dropped from analysis because of uncertainty about
his biological relationship to the family, and the affected
identical twins were counted as a single meiosis. Thus,
genotypes of 34 individuals were analyzed. The markers
with high heterozygosity and reliability for fine mapping
that were selected included some that had been geno-
typed in previous linkage studies for unrelated pheno-
types mapped to chromosome 2p (Sarfarazi et al. 1995;
Bejjani et al. 1998; Patel et al. 1998; Xiao et al. 2000).
Fluorescent primers purchased from Life Sciences were
used according to Research Genetics’ Genome Services
Protocol. Genotypes were obtained for all study partic-
ipants, both at seven original markers spanning a can-
didate region on chromosome 2p and at additional 2p
markers. In this second stage, genotypes at 19 of 21
selected marker loci were determined, including 7 from
the genome scan and 12 additional loci. The chromo-
some 2p markers analyzed, as well as their positions on
the Marshfield genetic map (Center for Medical Genet-
ics, Marshfield Medical Research Foundation; also see
Broman et al. 1998), are detailed in table 1. The PCR-
product lengths described as alleles (below) are those
produced by these primer pairs.
Linkage Analysis
LOD scores were calculated by the software package
FASTLINK, version 4.1P (Lathrop and Lalouel 1984;
Cottingham et al. 1993; Scha¨ffer et al. 1994). Somemul-
tipoint runs were done in parallel (Gupta et al. 1995),
with the aid of the p4 parallel-programming software
library (Butler and Lusk 1994) on a shared-memory–
multiprocessor computer. Loops in the pedigree were
broken by Becker et al.’s (1998) method. Inconsistencies
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Table 2
Models Used in Initial Marker Analysis
GROUP
PROPORTION OF INDIVIDUALS
Homozygous for
Nondisease Allele
Carrying at Least
One Disease Allele
Model 1:
Founders who married nonfounders 0 1.0
Unaffected founder couples and unaffected nonfounders:
Examined .01 .99
Not examined .03 .97
Individuals with CMC and/or thyroid disease .01 .99
Model 2:
Founders who married nonfounders 0 1.0
Unaffected founder couples and unaffected nonfounders .20 .80
Individuals with CMC .01 .99
Individuals with thyroid disease only .05 .95
Model 3:
Founders who married nonfounders 0 1.0
Unaffected founder couples and unaffected nonfounders 0 .33
Individuals with CMC 0 1.0
Individuals with thyroid disease only 0 .33
in the genotype data were detected by the PedCheck
program (O’Connell and Weeks 1998), and 10 (individ-
ual, marker) pairs were zeroed out in the genome-scan
marker data, in addition to all the pairs zeroed out in
the laboratory.
For every marker in the genome scan, two-point (i.e.,
marker and disease) LOD scores were computed by the
MLINK program. In the preliminary analysis, we used
equal allele frequencies for the markers and disease-allele
frequencies of .00001, for the dominant models, and
.005, for a recessive model. A low disease-allele fre-
quency was chosen to maintain a very low relative like-
lihood for scenarios in which a disease allele entered the
family more times than would be necessary to account
for all affected subjects.We analyzed all markers by three
dominant models and by the recessive analog of the first
dominant model (table 2). Models 2 and 3 were chosen
to avoid missing any relevant chromosomal regions. The
values of .20 and .80 in the second model imply a high
degree of diagnostic uncertainty with regard to unaf-
fected subjects. Model 3 assigns a very low penetrance
to unaffected subjects. The use of multiple simple screen-
ing models is in the spirit of the proposal presented by
Abreu et al. (1999)—that is, to screen with a dominant
model with 50% penetrance and with a recessive model
with 50% penetrance; however, their two genericmodels
are not well suited to our study, in which there was both
a rare (i.e., CMC) and a more common (i.e., thyroid)
manifestation of the same disease. Moreover, the pres-
ence of six parent-to-child transmissions strongly fa-
vored a dominant model over a recessive model (fig. 1).
A recessive model was considered in order to formally
rule out variants of APECED, which is recessive, and
because the seminal article on families with CMC (Wells
et al. 1972) has given the impression that the primary
mode of inheritance might be recessive.
Only a single region of the genome was consistent
with linkage. Varying the parameters for that region
showed that the following precautions were all unnec-
essary for study of this family:
1. distinguishing between documented and merely re-
ported unaffected status;
2. allowing for a phenocopy rate in affected indi-
viduals;
3. distinguishing between CMC and thyroid disease
in the second model;
4. assigning a high degree of diagnostic uncertainty
to unaffected individuals in the second model.
For all regions with a marker showing a two-point LOD
score 11.5 or for any two consecutive markers with
scores 11.0, we performed three-point analysis, using
LINKMAP.
For the fine-map analysis of 2p markers, with 34 gen-
otyped subjects, disease-allele frequency was assigned
the value .00001. Marker-allele frequencies were esti-
mated by the ILINK program in FASTLINK, with
marker-genotype data only (i.e., without phenotype
data). We used an autosomal dominant model of inher-
itance (table 3), with three penetrance classes.
Both the analysis of the partial data in the first phase
and the fact that 8 of the 11 affected individuals had
the rare, CMC phenotype suggested that inclusion of a
phenocopy rate would unnecessarily complicate the ba-
sic analysis. Since thyroid disease without CMC is not
so rare and may be hard to diagnose, we did consider
a modified model in which the three individuals with
thyroid disease only (i.e., without CMC) were assigned
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Table 3
Model Used in Fine Mapping
GROUP
PROPORTION OF INDIVIDUALS
Homozygous for
Nondisease Allele
Carrying at Least
One Disease Allele
Founders who married nonfounders 0 1.0
Unaffected founder couples and unaffected nonfounders 0 .8
Individuals with CMC and/or thyroid disease 0 1.0
a phenocopy rate of .02 and in which all the unaffected
and non–married-in individuals were assigned a diag-
nostic uncertainty of .01. The penetrance, .8, was esti-
mated according to established principles summarized
by Ott (1999). Of 23 offspring of either affected indi-
viduals or obligate nonpenetrant carriers, 11 were af-
fected. We added 0/1 for the founder couple in gener-
ation I, to get a fraction of 11/24. The simplest possible
penalty for ascertainment biased toward affected indi-
viduals is subtraction of 1 from both numerator and
denominator, but, in this situation, since the cases of an
affected mother and son had already been published
(Montes et al. 1971), we subtracted 2. Then we multi-
plied the numerator by 2 (because half the time the non-
disease allele is transmitted), to get a penetrance estimate
of 18/22, or .8.
Since ascertainment may have been biased toward
branches of the family with affected individuals, we as-
sessed the robustness of the .8 estimate by varying it in
the two-point LOD-score calculations (see the “Genetic
Linkage” subsection, in Results). For each pair of mark-
ers consistent with linkage at a recombination fraction
(v) of 0, a three-point analysis with the LINKMAP pro-
gram of FASTLINK 4.1P was performed to verify the
extent of the linked chromosomal interval. Most-likely
haplotypes were calculated by SIMWALK, version 2.82
(Sobel and Lange 1996).
Results
Immunologic Evaluations
Diverse patterns of abnormalities have been noted
among subjects with CMC (Kirkpatrick 2001). Immu-
nologic data for the family that we studied are sum-
marized in table 4. In subjects II-4 and III-8, cell-me-
diated immunity had been assessed by skin testing many
years ago, revealing anergy to candida and all other an-
tigens tested (Montes et al. 1971; T. P. Atkinson, un-
published data). In contrast, skin reactivity to candida
was more recently positive (∼20 mm induration) in af-
fected siblings IV-7, IV-8, and IV-9 (data not shown).
However, these children had no reactions to intradermal
challenge by tetanus, mumps, or trichophyton, although
all three had received the usual tetanus and mumps vac-
cinations and one had been culture positive for Tricho-
phyton species.
Flow-cytometric studies of lymphocyte subpopula-
tions in peripheral blood samples from subject III-8 that
were obtained years apart revealed a decreased per-
centage of CD8 T cells, producing a CD4:CD8 ratio
of 5–6 (normal ratio 2  0.5). Reduced numbers of
peripheral blood T cells, 889/mm3, along with an ele-
vated CD4:CD8 ratio, were also observed in his mother,
II-4. However, the affected children of III-8 had normal
numbers and percentages of CD4 and CD8 T cells
and B cells (not shown).
All the children of III-8, including the unaffected child,
IV-6, had serum IgM levels that were 1 SD below the
mean for age; in those sampled more than once, the
values appeared to be decreasing (table 4). Total IgG
levels of those affected with CMCwere normal to mildly
elevated, and IV-7 and IV-8 had mild elevations of IgE
(normal !50 IU/ml). Isohemagglutinins were present de-
spite the reduced levels of IgM (not shown). Previous
evaluations had documented positive antibody titers to
C. albicans in III-8 but not in his mother II-4. Both had
positive antibody responses to immunization with Sal-
monella typhi polysaccharide vaccine.
Proliferative responses to mitogens and antigens were
studied in affected siblings IV-7, IV-8, and IV-9, in
healthy subject IV-6, and in their mother, who had mar-
ried into the family. Mitogen responses were all normal,
but the responses to tetanus challenge in the three af-
fected children were undetectable, despite prior immu-
nization (table 4). Proliferative responses to candida are
positive in only approximately half of our laboratory
controls. In this family, positive proliferation, indicating
specific immunity to candida, occurred only in affected
subject IV-7 and in his mother.
PHA-induced IFN-g production was undetectable in
the healthy sibling (IV-6) and in the affected siblings (IV-
7, IV-8, and IV-9), although their mother and laboratory
controls had positive responses. Antigen-induced IFN-g
and TNF-a production by the affected children’s pe-
ripheral blood mononuclear cells in response to high
dose C. albicans antigen was robust, but they produced
no detectable IFN-g and relatively normal levels of TNF-
a in response to tetanus toxoid. Thus, both the patients’
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Table 4
Immunologic Data
SUBJECT (AGE [years])
STATUSa IMMUNOGLOBULIN
IN VITRO RESPONSES OF
PROLIFERATION/INF-g/TNF-a
IN RESPONSE TOa,b
CMC
Thyroid
Disease
Candida
Skin Test
IgMc
(mg/dl)
IgG
(mg/dl)
IgA
(mg/dl) Mitogensd Tetanus Candida
II-4 (55)    54 1,675 390 ND ND ND
III-8 (22)    51 1,405 192 ND ND ND
III-9 (33)   ND 80 954 104 //ND // //
IV-6 (12)    37 851 47 //ND // //
IV-7 (11)    29 938 41 //ND // //
IV-8 (10)    37 1,003 71 //ND // //
IV-9 (8)    34 1,039 118 //ND // //
a  p Present;  p absent.
b For INF-g and TNF-a, data are for production in culture supernatants. ND p not done.
c Mean  SD normal IgM levels are as follows: 3–5 years, 56  18; 6–8 years, 65  25; 9–11 years, 79  33; 12–16
years, 89  20; adult, 99  27 (Stiehm and Fudenberg 1966). Values 11 SD below the mean for age are underlined.
d PHA, ConA, and PWM.
Table 5
Two-Point LOD Scores for Markers on Chromosome 2
MARKER
LOD SCORE WHEN v BETWEEN DISEASE AND MARKER p
0 .01 .03 .05 .07 .10 .15
D2S2207 17.94 2.92 1.87 1.37 1.03 .69 .33
D2S1400 6.11 2.31 1.35 .91 .62 .34 .05
D2S131 16.34 5.18 3.73 2.96 2.43 1.86 1.22
D2S1360 5.05 1.29 .70 .39 .18 .05 .27
D2S320 .12 .05 .06 .15 .22 .30 .37
D2S405 1.09 .99 .84 .71 .60 .48 .32
D2S352 4.01 1.51 .95 .66 .46 .25 .03
D2S367 1.13 1.81 2.15 2.24 2.25 2.20 2.01
D2S1325 1.14 1.14 1.13 1.11 1.09 1.04 .94
D2S1788 3.31 3.26 3.17 3.07 2.97 2.80 2.50
D2S2328 3.70 3.65 3.54 3.42 3.30 3.11 2.77
D2S1356 3.23 3.19 3.09 2.99 2.88 2.71 2.40
D2S414 1.83 1.81 1.76 1.72 1.66 1.57 1.39
D2S119 1.65 1.64 1.61 1.58 1.54 1.48 1.35
D2S2174 2.58 2.56 2.52 2.47 2.41 2.29 2.07
D2S2240 3.14 1.52 1.03 .81 1.67 .54 .43
D2S2739 1.29 .32 .77 .97 1.08 1.17 1.20
D2S337 9.05 .27 .20 .41 .53 .64 .71
D2S441  4.35 2.89 2.21 1.76 1.29 .79
proliferative responses and their cytokine responses sug-
gested some ability to respond to candida but inconsis-
tent or low responsiveness to some of the other indi-
cators of intact cellular immunity. The in vitro responses
of subjects IV-6, IV-7, IV-8, and IV-9 were correlated
with their responses to candida and tetanus skin tests,
in contrast to the anergy seen in skin testing of their
father and paternal grandmother some years earlier.
Genetic Linkage
In the genome-scan two-point analysis, we found
regions worthy of follow-up on chromosomes 2, 4, and
17 in at least one dominant model and on chromosome
1 and 11 under a recessive model. The region on chro-
mosome 2 had five consecutive markers—D2S1360-
D2S405-D2S1788-D2S1356-D2S2739—spanning 130
cM, with positive scores in the first dominant model and
scores 11.0 in the second and third dominant models
(table 2). In models 2 and 3, the outside markers
D2S1360 and D2S2739 had scores 12.0. Three-point
analysis using all pairs of the five markers increased the
peak LOD score in the region. In contrast, the other four
regions considered had three or fewer adjacent markers
with positive scores, no markers with scores 12.0, and
three-point LOD scores that were lower than two-point
LOD scores. Therefore, we proceeded with fine mapping
of only the region on chromosome 2, using additional
family members and more markers to extend the
analysis.
In the family that we studied, linkage of CMC to
AIRE on chromosome 21 was investigated but not con-
firmed. In the genome scan, the two markers flanking
AIRE had two-point LOD scores !2.0 for v  .07
(complete data not shown). This was not surprising,
since the inheritance pattern for AIRE defects in APE-
CED is recessive, whereas the inheritance pattern in the
family that we studied appeared to be dominant. Fur-
thermore, the endocrinopathies in the family that we
studied were distinct from those in APECED.
Table 5 shows the two-point LOD scores for 19 mark-
ers on chromosome 2 when the parameters described for
the second phase are used. The markers are listed in map
order along the chromosome, except that the order of
D2S1360 and D2S320 is uncertain. Although theMarsh-
field map (Center for Medical Genetics, MarshfieldMed-
ical Research Foundation) is also uncertain about the
relative order of D2S367 and D2S1325, our data sug-
gest that D2S367 is closer to 2p-ter. All genotyped, affect-
798 Am. J. Hum. Genet. 69:791–803, 2001
Table 6
Two-Point LOD Scores at Varying Penetrance Values
MARKER (LOCATION [cM])
LOD SCORE AT PENETRANCE p
.5 .6 .7 .8 .9
D2S1325 (54.96) 1.79 1.66 1.47 1.14 .45
D2S1788 (55.51) 3.33 3.37 3.36 3.31 3.12
D2S2328 (61.00) 3.70 3.75 3.75 3.70 3.52
D2S1356 (64.29) 3.37 3.40 3.36 3.23 2.84
D2S414 (64.84) 2.20 2.15 2.04 1.83 1.35
D2S119 (65.39) 2.23 2.10 1.93 1.65 1.16
D2S2174 (67.58) 3.30 3.20 2.99 2.58 1.67
Table 7
Three-Point Linkage Analysis for Informative Markers
UPPER
MARKER
LOWER
MARKER
LOD SCORE
At Upper
Marker
At Lower
Marker Maximum
D2S1325 D2S2328 2.90 3.16 3.16
D2S1325 D2S414 2.68 3.05 3.05
D2S1325 D2S2174 2.41 3.03 3.03
D2S1788 D2S2328 3.21 3.57 3.57
D2S1788 D2S1356 3.82 3.77 3.82
D2S1788 D2S119 3.54 3.19 3.54
D2S1788 D2S2174 3.21 2.96 3.21
D2S2328 D2S1356 3.27 3.32 3.32
D2S2328 D2S414 3.15 3.02 3.15
D2S2328 D2S119 3.33 3.09 3.33
D2S2328 D2S2174 3.18 3.07 3.18
D2S1356 D2S414 3.06 2.75 3.06
D2S1356 D2S119 3.15 3.06 3.15
D2S1356 D2S2174 3.09 2.95 3.09
D2S414 D2S2174 3.02 3.08 3.08
ed individuals had the same allele at D2S1325, but, at
D2S367, the affected MZ twins did not share an allele
with the other affected individuals. The two-point LOD
scores at the seven markers defining the linked haplotype
varied, primarily because of differences in marker inform-
ativeness. Markers D2S1788, D2S2328, and D2S1356
had 9–10 distinct alleles in this family, whereas the other
four markers with positive scores at had only fivevp 0
or six alleles. Because thyroid disease is not rare in the
general population, we explored a modified model in
which the three individuals with only thyroid diseasewere
assigned a phenocopy rate of .02 and in which all the
unaffected and non–married-in individuals had a diag-
nostic uncertainty of .01. Under this model, the positive
two-point LOD scores shown in table 5 decreased by
0.05: for D2S1788, the LOD score at decreasedvp 0
from 3.31 to 3.27; for D2S2328, the LOD score at
decreased from 3.70 to 3.66; for D2S1566, thevp 0
LOD score at decreased from 3.23 to 3.20.vp 0
In the interval from D2S1325 through D2S2174, all
affected individuals shared an allele, producing posi-
tive two-point LOD scores at (table 5). We com-vp 0
puted most-likely haplotypes by using marker data only.
With different marker sets and random seeds, SIM-
WALK consistently predicted that the six-marker hap-
lotype D2S1788 (190 bp)–D2S2328 (148 bp)–D2S1356
(241 bp)–D2S414 (215 bp)–D2S119 (225 bp)–D2S2174
(280 bp) segregated in all affected individuals. III-5, IV-
2, and IV-3, the individuals whose genotypes defined the
boundaries of the linked interval, were ascertained in the
second, fine-mapping phase, explaining why the linked
interval appeared to be larger when only the initial 20
DNA samples were used in the genome scan. The hap-
lotype shared among affected subjects was used to make
a genetic diagnosis for three infant offspring of family
members who have either CMC or thyroid disease (not
shown).
A penetrance of .8 for the disease allele was estimated
on the basis of data on the family (see the “Linkage
Analysis” subsection of Subjects and Methods) but may
be inaccurate. To determine the effect that penetrance
had on our linkage analysis, we recalculated the two-
point LOD scores at , varying the penetrance fromvp 0
.5 to .9 (table 6). As shown, the penetrance value giving
the highest LOD score was not uniformly .8 but, instead,
varied from marker to marker. For each of the pene-
trance values used, a least two and as many as four
markers had LOD scores 13.0.
The sensitivity-testing method of Hodge and Green-
berg (1992) was used to evaluate the effect of possible
misclassification on the LOD score. Using a penetrance
estimate of 75% (to approximate what the estimate
would have been with one fewer affected individuals),
we changed the status of each of the 11 affected indi-
viduals (the twins counting as one) to unaffected and
repeated the two-point analysis for the highest-scoring
marker, D2S2328. When the disease status of none of
the affected individuals was changed, the LOD score was
3.73. Changing one individual at a time gave the fol-
lowing LOD scores: 3.73 (II-4), 3.73 (III-8), 3.73 (III-
13), 3.73 (III-14), 3.24 (IV-2), 3.03 (IV-6, IV-7, or IV-
8), 3.07 (IV-10), 2.90 (IV-13), and 3.07 (IV-14). The
effect of misdiagnosing any of the four affected individ-
uals in generations II and III was negligible because,
having had affected descendants, they were expected to
carry the disease-associated allele. The effect of misdi-
agnosing the twin (IV-2) was less severe than the effect
of misdiagnosing other individuals in generation IV, be-
cause, for purposes of the linkage analysis, IV-3 was
ignored, and thus IV-2 had no other affected individuals
in her nuclear family. The effect of misdiagnosing IV-13
was the most severe, because IV-13 has a child carrying
the disease-associated allele whose disease status in the
analysis was classified as unknown.
Three-point linkage analysis showed positive LOD
scores when all 21 pairs of markers among D2S1325,
D2S1788, D2S2328, D2S1356, D2S414, D2S119, and
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D2S2174 were used. Scores for the more informative
marker pairs are shown in table 7. The highest three-
point score, 3.82, was achieved, not surprisingly, with
the two highly informative markers that were farthest
apart. These three-point LOD scores suggest that no
subinterval of the linked marker interval should be fa-
vored as likely to contain the locus conferring suscep-
tibility to CMC and/or thyroid disease.
Discussion
We have presented a large family with an autosomal
dominant form of CMC associated with thyroid disease,
and we have localized the underlying gene defect to chro-
mosome 2p. This is the first linkage assignment for au-
tosomal dominant CMC. The characteristics of the dis-
order in the family that we studied are different, in
several respects, from those of APECED, the only CMC-
associated disorder for which a gene has been identified.
Although both conditions have the common findings of
CMC and endocrinopathy, APECED is well established
as an autosomal recessive disorder, and no variants with
autosomal dominant transmission are known. In addi-
tion, patients with APECED typically present with ad-
renal failure and hypoparathyroidism, endocrine disor-
ders not seen in the family that we studied. Finally,
APECED is due to mutations in AIRE, located on chro-
mosome 21q22.3, a region that, in the family that we
studied, did not show segregation with disease. In this
family, we established genetic linkage to a 15-cM region
on chromosome 2p, bounded by markers D2S367 and
D2S2240. Data on more families segregating CMC/thy-
roid disease could make possible the identification of
critical recombination events to narrow the linkage
interval.
Published studies suggest that autosomal dominant
CMC (MIM 114580) may be common among patients
who do not have APECED. A family reported by Sams
et al. (1979) and Jorizzo et al. (1980) demonstrated
autosomal transmission of CMC, with no recognized
endocrinopathy, in three children and four grandchil-
dren of an affected subject. In another family, an 11-
year-old boy, his sister, and her daughter had CMC
without reported endocrine abnormalities (Canales et
al. 1969). Loeys et al. (1999) reported a 5-year-old child
with CMC and invasive fungal disease (a mycotic an-
eurysm) who had an affected father and an affected
paternal grandmother. The syndrome of the family that
we studied, in which thyroid disease is frequent, appears
to be distinct from autosomal dominant CMC assigned
to MIM 114580, which is characterized by a lack of
associated endocrinopathy.
An association between thyroid disease and CMChas
been recognized in familial CMC. Kroll et al. (1973)
described a mother with CMC whose son had CMC
and previously undiagnosed hypothyroidism. In a re-
view of 43 patients with CMC who were from eight
centers, Herrod (1990) noted three instances of appar-
ent dominant transmission: an affected grandmother,
mother, and son (the latter of whom had hypothyroid-
ism); an affected father-daughter pair; and an affected
father and three siblings. Herrod stated that, in the cases
with dominant inheritance, endocrinopathy appeared to
be uncommon, although this may reflect the high in-
cidence of endocrinopathy in families with recessive
APECED that were reported in his review. In a recent
case report, Steensma et al. (2000) documented auto-
somal dominant CMC in which the proband, a 27 year-
old man, was also found to have subclinical hypopara-
thyroidism and hypogonadism.
Other series and case reports document the occur-
rence of CMC and hypothyroidism without adrenal or
parathyroid dysfunction (Papazian and Koch 1960;
Montes et al. 1971; Kirkpatrick and Smith 1974). Hy-
pothyroidism constitutes only ∼6% of endocrine ab-
normalities seen in APECED, and almost all patients
with hypothyroidism and APECED have hypoparathy-
roidism and/or adrenal failure as well (Ahonen et al.
1990). An isolated patient with CMC and hypothy-
roidism, especially one from a family with multiple af-
fected individuals other than siblings, is unlikely to have
a mutation in the AIRE gene. Thus, although less well
recognized than APECED, dominant CMC, sometimes
associated with thyroid disease, is a distinct clinical
entity.
Immunologic evaluation did not reveal a uniform pat-
tern of abnormalities in the family that we studied, al-
though in aggregate the studies suggested the possibility
of mild T-cell and B-cell dysfunction in those affected
with CMC. The most consistent feature was depressed
serum concentration of IgM. Although Gill and Portnoy
(1989) reported the development of panhypogamma-
globulinemia in a patient with CMC and hypothyroid-
ism, low serum IgM has not previously been a notable
abnormality in immunologic studies of CMC (Herrod
1990). Low IgG, low IgA, and selective IgA deficiency
have been separately identified in patients with CMC
(Herrod 1990; Lilic et al. 1996) but were not docu-
mented in the family that we studied. One reported
patient with CMC and hypothyroidism had severe IgG-
subclass deficiencies and deficient anti-polysaccharide
antibody responses, resulting in the development of
bronchiectasis (Bra¨gger et al. 1989). It is not clear
whether antibody deficiencies in CMC are part of a
primary immunologic disorder or perhaps a conse-
quence of the long-term immunosuppressive effects of
chronic fungal infections.
As has been demonstrated with most other patients
with CMC, those in the family that we studied exhibited
aberrant T-cell responses. The majority of patients with
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CMC manifest cutaneous anergy to candida antigen
and, in many cases, to other antigens as well (Herrod
1990). Although, by skin testing, the patients in gen-
erations II and III whom we tested were anergic to other
delayed-type antigens (in parallel to their poor responses
to tetanus in vitro), there was a curious disparity be-
tween the children in generation IV and their father and
paternal grandmother. The younger patients manifested
robust delayed-type–hypersensitivity responses to can-
dida antigen, which mirrored their positive cytokine
production in vitro, whereas the adults were anergic to
all intradermally administered antigens tested. These
differences may be a explained by a progressive dete-
rioration of T-cell responses with increasing age in pa-
tients with CMC, as has been suggested by others (Sams
et al. 1979). Alternatively, the superior responses seen
in the children could be the result of better recent man-
agement of their infections, bymeans of azole antifungal
therapy. Candida-derived polysaccharide antigens have
been shown to be immunosuppressive (Fischer et al.
1978, 1982; Durandy et al. 1987), and improved im-
mune responses are recognized to follow resolution of
fungal infections (Paterson et al. 1971; Kirkpatrick and
Smith 1974; Durandy et al. 1987; Kirkpatrick 2001).
Because early, effective treatment of fungal infections
may confer significant benefit, genetic counseling was
offered, and inheritance of the affected or unaffected
haplotype (as determined in a CLIA-certified labora-
tory) was shared with parents of infants who were too
young for ascertainment of disease status.
Our account has focused on the CMC phenotype,
but, in some individuals in the family, only thyroid dys-
function was documented. Previous linkage studies have
indicated that Graves disease (MIM 275000) and Hash-
imoto thyroiditis (MIM 140300) are associated with
several genes of the immune system, such as the CTLA4
gene on chromosome 2q33 (Donner at al. 1997; He-
ward et al. 1999; Vaidya et al. 1999), as well as with
additional loci, on 18q21 (Vaidya et al. 2000) and 20q1
(Tomer et al. 1999b, 1999; Pearce et al. 1999). Hash-
imoto thyroiditis and other types of thyroiditis or hy-
pothyroidism have been associated with 6p (Heward et
al. 1998), 5q31-q33 and 8q23-q24 (Sakai et al. 2001),
14q31 (Tomer et al. 1998a), Xq21 (Barbesino et al.
1998), and chromosomes 12 and 13 (Tomer et al. 1999).
However, none of these studies found evidence for ge-
netic linkage of thyroid disease alone to chromosome
2p.
According to the publicly available Draft Human
Genome sequence (International Human Genome Se-
quencing Consortium 2001), the 15-cM interval be-
tween D2S367 and D2S2240 spans ∼12 Mb and con-
tains 120 actual and predicted genes, as well as dozens
of mRNAs and expressed-sequence tags. Some of these
genes—such as CYP1B1 (MIM 601771), SLC3A1/
rBAT (MIM 104614), and SIX3 (MIM 603714)—are
unlikely candidates for candidiasis/thyroid disease be-
cause they are known to be mutated in patients with
completely different phenotypes (Calonge et al. 1994;
Stoilov et al. 1997; Wallis et al. 1999). However, the
nature of the gene that has become mutated in the
family that we studied is obscure.
The mechanism by which AIRE deficiency leads to
failure of selected endocrine tissues remains poorly un-
derstood. The gene product is expressed at highest levels
in thymus and glandular tissues. Histopathology shows
glandular atrophy and lymphocytic infiltrates with oc-
casional lymphoid follicles and fibrosis (Whitaker et al.
1956; Hermans et al. 1969), changes consistent with ei-
ther a primary autoimmune reaction against glandular
tissue or a reactive process developing as the gland is
damaged by another mechanism. Autoantibodies are not
uniformly found in patients with APECED, although ap-
pearance of anti-adrenal or anti-steroidal–cell antibodies
presages the development of adrenal failure or ovarian
failure in APECED (Ahonen et al. 1987; Bjo¨rses et al.
1998). One of our affected pediatric patients who had
both markedly elevated TSH and cystic changes in the
thyroid nevertheless had no detectable anti-thyroid an-
tibodies. In addition, another family member was diag-
nosed with Riedel thyroiditis, a rare fibrosing thyroid
condition that may not have an autoimmune pathogen-
esis (Zimmermann-Belsing and Feldt-Rasmussen 1994).
Thus, an inflammatory or degenerative process that, for
reasons other than autoimmunity, arises in the thyroid
could result in hypothyroidism with or without auto-
antibodies or lymphocyte infiltration. The genetic ap-
proach to identification of the molecular defect in au-
tosomal dominant CMC/thyroid disease may provide
clues to the pathogenesis not only of the disorder in the
family that we studied but of other CMC syndromes as
well.
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